Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.

Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...

In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

This year’s Conference on Retroviruses and Opportunistic Infections (CROI) features several sessions discussing prevention ...

The Federal Executive Council (FEC) rose from its second meeting in three days yesterday with the approval of N10.299 billion for the procurement of diagnostic kits for diabetes, anti retroviral drugs ...